Used in research for its ability to inhibit cholesteryl ester transfer protein (CETP), torcetrapib was developed to increase high-density lipoprotein (HDL) cholesterol and decrease low-density lipoprotein (LDL) cholesterol. It was investigated as a potential treatment for cardiovascular diseases, aiming to reduce the risk of heart attacks and atherosclerosis. Despite promising early results, clinical trials were halted due to increased adverse events, including higher mortality and blood pressure issues. It is no longer pursued for therapeutic use but remains relevant in scientific studies exploring lipid metabolism and CETP inhibition mechanisms.